Form D · Biotechnology
Relieve Genetics, Inc.
San Francisco, CA · CIK 0001671663
Offering snapshot reported Apr 11, 2016 · SEC filing
- Reported sold
- $4.33M Offering amount: $17.3M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 30, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 11, 2016 | Initial | $4,333,713 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-260976
Source: Form D, filed Apr 11, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jose Haresco | Director |
| Craig Johnson | Director, Executive |
| David Mauney | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
600 Montgomery Street Suite 1700
San Francisco, CA, 94111
San Francisco, CA, 94111